Fierce Competition Requires Precision in Meeting the Needs of the Coagulation Factor Market

With potentially more than 20 products in the recombinant coagulation factors market within 5 to 6 years, it will be mandatory to meet the needs of a US$ 6.2 bln market in 2010 in order to gain a relevant market share

SITGES, Spain | October 26, 2011 | The Business Intelligence firm La Merie S.L. conducted its 3rd analysis of the coagulation factor market and R&D pipeline and benchmarked the product target profiles by a market research study among haemophilia specialists. The target pipeline analysis showed that the number of clinical stage projects of recombinant coagulation factors doubled to more than 22 within one year. The first regulatory files have been submitted and regulatory approvals in all classes of recombinant coagulation factors are feasible within the next four years.

The global market of recombinant coagulation factors was US$ 6.2 bln in 2010 and showed a continuous annual growth rate of 8.5% over the last 5 years. Given the strong pipeline activities, the recombinant coagulation factor market may become overcrowded with nearly 30 new and established products from more than 10 different suppliers within 5 to 6 years. The fierce competition for market shares makes it mandatory to meet the needs of the market with clear differentiation factors.

The primary target profile of novel recombinant coagulation factors puts emphasis on reducing the administration frequency by prolongation of the half-life which is easily
measurable in experimental and clinical studies. However, the market survey among hematologists revealed a different priority for which the study participants would accept a higher price. Physicians would not accept higher annual treatment costs for a less frequent administration regimen. And if once-weekly dosing were not feasible, additional advantages will be required to sell the product.

These results and more were found in the search conducted by La Merie. The report can be acquired at La Merie’s online store (www.pipelinereview.com). The report “Coagulation Factors 2011 – who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis” provides a description, evaluation and assessment of the recombinant coagulation factor R&D pipelines as of October 2011. The authors analyze and assess the target pipeline for each of the coagulation factors for haemophilia and work out the target profiles of development projects. A market research study was conducted to challenge industry’s target profiles and evaluate the sensitivity for pricing. The report is built upon primary and secondary search for information and use of a proprietary database and news portal. A market survey was conducted among haematologists from haemophilia care centers. In house analysts with experience in biopharmaceutical R&D and business development authored the report and analysed and assessed the findings.

About La Merie

La Merie S.L. is a Business Intelligence enterprise dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com.